Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
Phase NA Completed
45 enrolled 13 charts
ARIS
Completed
350 enrolled
ROOT
Completed
167 enrolled
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Phase NA Completed
16 enrolled 9 charts
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Phase 2 Withdrawn
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
Phase 2 Withdrawn
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Phase 3 Suspended
480 enrolled
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
Phase 2 Withdrawn
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
Phase 1/2 Unknown
Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
Phase 2 Withdrawn
Antineoplaston Therapy in Treating Patients With Colon Cancer
Phase 2 Withdrawn
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Phase 2 Withdrawn
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Phase 2 Withdrawn
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Phase 2 Withdrawn
Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer
Phase 2 Withdrawn
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery
Phase 3 Completed
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
Phase 2 Terminated
51 enrolled
Celecoxib in Preventing Skin Cancer
Phase 2 Withdrawn
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
Phase 1 Terminated
15 enrolled
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 2 Terminated
46 enrolled
NHL
Phase 1 Unknown
50 enrolled
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Phase 1 Unknown
40 enrolled
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Phase 1 Unknown
50 enrolled
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Phase 2 Unknown
30 enrolled